Specifically, successful clinical trials led by Grupp et al. treating acute lymphoblastic leukemia (ALL) using CD19-targeted CAR T-cells led to its FDA approval in 2017 (178). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.